LungLife AI, Inc. (9H4.F)
- Previous Close
0.3380 - Open
0.3060 - Bid 0.2960 x --
- Ask 0.4220 x --
- Day's Range
0.3060 - 0.3380 - 52 Week Range
0.2080 - 1.5600 - Volume
1 - Avg. Volume
0 - Market Cap (intraday)
11.017M - Beta (5Y Monthly) -0.20
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
LungLife AI, Inc., a diagnostic company, researches and develops clinical diagnostic solutions for lung cancer with artificial intelligence (AI) technology in the United States and the People's Republic of China. It engages in developing LungLB, a blood-based test to stratify cancerous and benign lung nodules identified by CT scan. The company was formerly known as Cynvenio Biosystems, Inc. and changed its name to LungLife AI, Inc. in May 2019. LungLife AI, Inc. was incorporated in 2009 and is based in Thousand Oaks, California.
lunglifeai.com15
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 9H4.F
Performance Overview: 9H4.F
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 9H4.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 9H4.F
Valuation Measures
Market Cap
11.06M
Enterprise Value
8.74M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
200.43
Price/Book (mrq)
1.40
Enterprise Value/Revenue
189.96
Enterprise Value/EBITDA
-1.71
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-28.69%
Return on Equity (ttm)
-51.42%
Revenue (ttm)
46k
Net Income Avi to Common (ttm)
-5.41M
Diluted EPS (ttm)
-0.2000
Balance Sheet and Cash Flow
Total Cash (mrq)
2.83M
Total Debt/Equity (mrq)
4.37%
Levered Free Cash Flow (ttm)
-3.06M
Company Insights: 9H4.F
9H4.F does not have Company Insights